Sieglinde M Müllers1, Fionnuala M McAuliffe2, Etaoin Kent3, Stephen Carroll4, Fionnuala Mone4, Noelle Breslin5, Jane Dalrymple5, Cecelia Mulcahy4, Keelin O'Donoghue6, Aisling Martin7, Fergal D Malone3. 1. Obstetrics & Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: siglindemuellers@rcsi.ie. 2. UCD Obstetrics & Gynecology, School of Medicine and Medical Science, University College Dublin, National Maternity Hospital, Dublin, Ireland. 3. Obstetrics & Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland. 4. Obstetrics & Gynecology, National Maternity Hospital, Dublin, Ireland. 5. Obstetrics & Gynecology, Rotunda Hospital, Dublin, Ireland. 6. Obstetrics & Gynecology, University College Cork, Cork University Maternity Hospital, Cork, Ireland. 7. Obstetrics and Gynecology, The Coombe Women and Infants University Hospital, Dublin, Ireland.
Abstract
OBJECTIVE: With the recognition of the role of fetoscopic laser ablation for twin to twin transfusion syndrome (TTTS), there is a requirement for auditable standards for this technically challenging and specialized treatment. The purpose of this study is to report on the perinatal and medium-term neurodevelopmental outcomes following an 8-year national single center experience in the management of TTTS using the selective fetoscopic laser ablation technique. STUDY DESIGN: An audit of all cases of TTTS treated with selective laser ablation by a single national fetal medicine team was performed. Overall perinatal survival and medium-term neurodevelopmental outcomes were reported and correlated with gestational age at diagnosis, placental location, volume of amnio-reduction, Quintero staging and percentage inter-twin growth discordance. Procedure-related complications were recorded. RESULTS: The overall fetal survival for the first 105 consecutive cases of TTTS was 61% (128/210 fetuses). Dual survival occurred in 47% (49/105) of cases, and with a single survival rate of 28% (30/105), perinatal survival of least one infant was achieved in 75% (79/105) of cases. No correlation was found between any clinical or sonographic marker and perinatal outcome, although dual survival was noted to be significantly decreased with increasing Quintero stage (p=0.041). Currently, 86% of survivors have been reported to have a normal medium-term neurological outcome. CONCLUSION: Fetoscopic laser ablation is the established optimal treatment for severe twin to twin transfusion syndrome (TTTS). We report comparable short and medium-term outcomes following the selective fetoscopic technique comparing results from our national program with internationally published single-center outcomes, supporting the efficacy and safety of this treatment at our center.
OBJECTIVE: With the recognition of the role of fetoscopic laser ablation for twin to twin transfusion syndrome (TTTS), there is a requirement for auditable standards for this technically challenging and specialized treatment. The purpose of this study is to report on the perinatal and medium-term neurodevelopmental outcomes following an 8-year national single center experience in the management of TTTS using the selective fetoscopic laser ablation technique. STUDY DESIGN: An audit of all cases of TTTS treated with selective laser ablation by a single national fetal medicine team was performed. Overall perinatal survival and medium-term neurodevelopmental outcomes were reported and correlated with gestational age at diagnosis, placental location, volume of amnio-reduction, Quintero staging and percentage inter-twin growth discordance. Procedure-related complications were recorded. RESULTS: The overall fetal survival for the first 105 consecutive cases of TTTS was 61% (128/210 fetuses). Dual survival occurred in 47% (49/105) of cases, and with a single survival rate of 28% (30/105), perinatal survival of least one infant was achieved in 75% (79/105) of cases. No correlation was found between any clinical or sonographic marker and perinatal outcome, although dual survival was noted to be significantly decreased with increasing Quintero stage (p=0.041). Currently, 86% of survivors have been reported to have a normal medium-term neurological outcome. CONCLUSION: Fetoscopic laser ablation is the established optimal treatment for severe twin to twin transfusion syndrome (TTTS). We report comparable short and medium-term outcomes following the selective fetoscopic technique comparing results from our national program with internationally published single-center outcomes, supporting the efficacy and safety of this treatment at our center.
Authors: Christie Bolch; Michael Fahey; Dinah Reddihough; Katrina Williams; Susan Reid; Angela Guzys; Stephen Cole; Andrew Edwards; Alison Fung; Ryan Hodges; Ricardo Palma-Dias; Mark Teoh; Susan Walker Journal: BMC Pediatr Date: 2018-08-01 Impact factor: 2.125
Authors: Adalina Sacco; Lennart Van der Veeken; Emma Bagshaw; Catherine Ferguson; Tim Van Mieghem; Anna L David; Jan Deprest Journal: Prenat Diagn Date: 2019-02-27 Impact factor: 3.050
Authors: So Yeon Kweon; Seung Mi Lee; Keumran Cho; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun Journal: J Korean Med Sci Date: 2019-01-07 Impact factor: 2.153